Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer

PURPOSE: Circulating tumor DNA (ctDNA) sequencing provides a minimally invasive method for tumor molecular stratification. Commercial ctDNA sequencing is increasingly used in the clinic, but its accuracy in metastatic prostate cancer is untested. We compared the commercial Guardant360 ctDNA test aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Taavitsainen, Sinja, Annala, Matti, Ledet, Elisa, Beja, Kevin, Miller, Patrick J., Moses, Marcus, Nykter, Matti, Chi, Kim N., Sartor, Oliver, Wyatt, Alexander W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446428/
https://www.ncbi.nlm.nih.gov/pubmed/32914020
http://dx.doi.org/10.1200/PO.19.00014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446428/
https://www.ncbi.nlm.nih.gov/pubmed/32914020
http://dx.doi.org/10.1200/PO.19.00014

Ejemplares similares